Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Benefits of Spironolactone: Win Ratio Analysis of the TOPCAT Trial
Author(s): Dung Viet Nguyen , Hoai Thi Thu Nguyen Added: 7 months ago

Heart Failure
Neutral Outcomes of Routine Colchicine and Spironolactone Treatments in MI Patients
Added: 1 year ago Source:  Radcliffe Cardiology
AUTHOR: Yazmin Sadik; Special Editor: Greg GuilloryAmerican Heart Association, 17th Nov, 2024 –The CLEAR-SYNERGY (OASIS 9) (Population Health Research Institute; NCT03048825) trial investigated long-term treatment with spironolactone verses placebo and colchicine verses placebo following percutaneous coronary intervention (PCI) in patients with myocardial infarction (MI).CLEAR-SYNERGY (OASIS 9)… View more

Prevention & Chronic Conditions

Intervention
AHA 24 Late-Breaking Discussion: REALIZE-K
Author(s): Harriette Van Spall , Mikhail Kosiborod Added: 1 year ago
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone.Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).REALIZE-K is a phase 4… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
ESC 24: MRAs in Heart Failure
Author(s): Added: 1 year ago
ESC Congress 2024 — MRAs reduce the risk of cardiovascular events in patients with HF, HFpEF and HFrEF.Prof Pardeep Jhund (University of Glasgow, UK) joins us to discuss findings from a study investigating mineralocorticoid receptor antagonists (MRAs) across different types of heart failure.This pre-specified, patient-level meta-analysis of RALES (spironolactone), EMPHASIS-HF (eplerenone), TOPCAT… View more

Heart Failure
Mineralocorticoid Receptor Antagonists in Heart Failure
Author(s): Rishi Sethi , Pravesh Vishwakarma , Akshyaya Pradhan Added: 1 year ago

MI/ACS

Heart Failure
Masterclass with Dr Van Spall: Professor Zannad on Globalising Heart Failure Evidence
Author(s): Faiez Zannad , Harriette Van Spall Added: 4 weeks ago
In this episode of Masterclass, host, Dr Harriette Van Spall speaks with Professor Faiez Zannad about the challenge of making heart failure evidence more globally representative.Professor Zannad is an emeritus Professor of Therapeutics and Cardiology at the University of Lorraine in Nancy, France, and a leading clinical trialist in heart failure whose studies have informed international treatment… View more

Heart Failure
AHA 25: The POLY-HF Trial
Author(s): Ambarish Pandey Added: 7 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not… View more

Heart Failure
Finerenone: Will It Be a Game-changer?
Author(s): Dinesh Khullar , Anish Kumar Gupta , Kulwant Singh Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Aldosterone and Potassium in Heart Failure
Author(s): Laibah Arshad Khan , Adeena Jamil , Stephen J Greene , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
The Aldosterone Story: New Chapters
Author(s): Vijay Chopra Added: 10 months ago

Heart Failure